SEMA3F positivity was linked to improved patient survival (median OS: 38.9 months vs. 26.5 months), aligning with similar findings observed in esophageal and oral squamous cell carcinoma cases14,17. This evidence concerns the gene SEMA3F and oral cavity squamous cell carcinoma.